155TiP A randomised phase II trial of neoadjuvant multi-agent chemotherapy (CHT) OR patritumab deruxtecan (HER3-DXd; U3-1402) +/- endocrine therapy (ET) for high-risk hormone receptor-positive (HR+/HER2-) early breast cancer (EBC): SOLTI-2103 VALENTINE trial
Mafalda Oliveira(Vall d'Hebron Institut de Recerca), Aleix Prat(Hospital Clínic de Barcelona), David Sternberg(Daiichi Sankyo (United States)), Xavier González(Breast Cancer Research Foundation), Guillermo Villacampa(Vall d'Hebron Institut de Recerca), J.M. Ferrero-Cafiero(Solti), M. Borrell Puy(Vall d'Hebron Hospital Universitari), Tomás Pascual(Breast Cancer Research Foundation), K. Amillano Parraga(Hospital Universitari Sant Joan de Reus), Rodrigo Sánchez-Bayona(Research Institute Hospital 12 de Octubre), Pang‐Dian Fan(Daiichi Sankyo (United States)), Mireia Margelí Vila(Institut Català d'Oncologia), A. Santhanagopal(Daiichi Sankyo (United States)), Montserrat Muñoz-Mateu(Consorci Institut D'Investigacions Biomediques August Pi I Sunyer), A. Perelló Martorell(Hospital Universitario Son Espases), Yenlik Zheteyava(Daiichi Sankyo (United States)), M.E. Pérez López(Complexo Hospitalario Universitario A Coruña), Clara Martínez-Vila(Althaia), P. Tolosa Ortega(Hospital Universitario 12 De Octubre), Juan Miguel Cejalvo(Universitat de València)
Cited by 6
Related Papers
Trastuzumab Deruxtecan in Previously Treated HER2-Low Advanced Breast Cancer
|New England Journal of Medicine|2022|2.5k
Phenotypic and molecular characterization of the claudin-low intrinsic subtype of breast cancer
|Breast Cancer Research|2010|2.1k
Tucatinib, Trastuzumab, and Capecitabine for HER2-Positive Metastatic Breast Cancer
|New England Journal of Medicine|2019|1.3k
4th ESO–ESMO International Consensus Guidelines for Advanced Breast Cancer (ABC 4)
|Annals of Oncology|2018|1.2k